Posts Tagged: medical diagnostics

Miroculus acquires Kapplex to advance diagnostics for complex diseases

Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto. This announcement was covered in GenomeWeb and PeHub. When ... Read more

Global University Venturing features MaRS Innovation’s unique model for technology transfer

MaRS Innovation's "model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding," writes Thierry Heles in, "MaRS Innovation: A Unique Model for Tech Transfer," for Global University Venturing. This feature was also covered in Techopia. The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015. Here's an excerpt exploring the range of MI's portfolio and Hofstein's strategy for addressing technologies emerging in new ... Read more

Xagenic announces $15 million financing round with Series B investors

TORONTO (July 9, 2015) — Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for point-of-care use, today announced that it has raised $15 million (CAD). Each of the company's Series B investors has participated in this financing, including Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation. PE Hub, Cantech Letter, Genome Web, Fierce Medical Devices and the Wall Street Journal's Venture Capital Dispatch blog covered this announcement. In June, Xagenic also announced it has acquired ... Read more

MaRS Innovation forms third collaboration with Johnson & Johnson Innovation

MaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest. The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615). This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech. Earlier this year, Johnson & Johnson Innovation and ... Read more

Xagenic founder Shana Kelley’s MRI blog post on bringing research to market

U of T professor shares tips to her team's commercialization success When it comes to bringing research from the lab to the market, the University of Toronto’s Dr. Shana Kelley knows firsthand what it takes. She’s co-founder of Xagenic, a MaRS Innovation and U of T start-up company that’s developed the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on her research with fellow U of T colleague Professor Edward Sargent. Xagenic recently announced a Series B financing announcement following their successful $10 million ... Read more

MaRS Innovation Announces Collaboration with Johnson & Johnson Innovation

Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health TORONTO, Nov. 25, 2013 - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics. This announcement was covered by Biotechnology Focus and the Village Gamer blog. Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly ... Read more

MaRS Innovation launches streamlined funding program

Applications invited for MI’s Industry Access Program, which matches early-stage, high-potential technologies to partners and funding MaRS Innovation (MI) has launched a unique funding program to match researchers with industry partners while advancing early stage technologies: the MaRS Innovation Industry Access Program (MI-IAP). This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI's partners to review a wide range of remarkable technologies within the Toronto academic ... Read more

MaRS Innovation focus of Yonge Street Media article on growing technology sectors

President and CEO Dr. Raphael Hofstein speaks on healthcare innovation in Toronto In an October 30 article, Yonge Street Media's Andrew Seale spoke with MI’s president and CEO Raphael Hofstein on the booming healthcare innovation coming from Toronto since 2005. Seale's article is the first of a two-part series on technological innovation. In the article, Hofstein credits the city’s intellectual infrastructure and access to healthcare resources for allowing innovation to flourish. Three of MI’s start-up companies are also mentioned in the article. Here’s an excerpt (links and ... Read more

ChipCare’s handheld analyzer attracts one of Canada’s largest-ever healthcare angel investments

Device could significantly improve HIV diagnostics in developing world OTTAWA, September 16, 2013 — An innovative, handheld point-of-care analyzer, developed by ChipCare Corporation, has secured one of the largest ever angel investments in Canada's healthcare sector. Phase II financing has closed, with an investment of $2.05M to support ChipCare's continuing development and commercialization over the next three years. Media coverage: Biotechnology Focus, TechVibes, BetaKit, Healthrender, Crunchbase, Toronto Star and VentureLab. The financing evolved through a uniquely collaborative funding model among Canadian social angel investors, including ... Read more

Dr. Hofstein’s Op-Ed for The Hill-Times, “Biotechnology research: A knowledge economy”

This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9: Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy. Canada has the holistic approach and translational research necessary to address health care’s pervasive ... Read more
Page 1 of 212